The preparation and properties of niosomes—non-ionic surfactant vesicles

Baillie, A. J.; Florence, Alexander T.; Hume, Lisbeth R.; Muirhead, G T; Rogerson, Alan

doi:10.1111/j.2042-7158.1985.tb04990.x

Cited by 376 publications

(213 citation statements)

References 13 publications

Supporting

Mentioning

206

Contrasting

Unclassified

Order By: Relevance

“…It was therefore possible to derive the amount of adriamycin entrapped by the niosomes (-70%). The stability of niosome encapsulated adriamycin and drug release rates have been estimated for niosomes suspended in serum and PBS and prolonged release has been demonstrated (Baillie et al, 1985). Murine pharmacokinetic studies WIL, a human squamous lung tumour xenograft (Merry et al, 1988) was serially passaged in 100mg fragments into nude mice bred from the Department's colony.…”

Section: Methodsmentioning

confidence: 99%

“…Preparation and c-haracterisation of niosomes Niosomes were prepared by the hand-shaking and etherinjection techniques which have been described previously (Baillie et al, 1985).…”

Section: Methodsmentioning

confidence: 99%

“…More recent work with adriamycin (Florence et al, 1988) has also indicated that both organ distribution and metabolic patterns are changed by administration of the drug niosomes. The methods of preparation and pharmaceutical properties of niosomes have been reported in detail in previous papers (Baillie et al, 1985) and these preparations are used here. In this paper the effect of niosomal encapsulation on the pharmacokinetics and activity of adriamycin in human lung tumour cells grown in monolayer, spheroids and nude mice xenografts is reported.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer, spheroid and xenograft

Rogerson²,

Morrison³

et al. 1988

Br J Cancer

Self Cite

View full text Add to dashboard Cite

Summary Niosomes are multilamellar vesicles formed from nonionic surfactants of the alkyl or dialkyl polyglycerol ether class and cholesterol. Adriamycin has been trapped within vesicles prepared from a monoalkyl triglycerol ether and its activity compared with adriamycin solution in human lung tumour cells grown in monolayer and spheroid culture and in tumour xenografted nude mice. The activity of the encapsulated adriamycin in vitro is maintained with similar clonogenic survival curves following treatment of monolayers and identical growth delays following spheroid exposure. The pharmacokinetics of adriamycin are altered in vivo in human lung tumour-bearing nude mice, when it is administered in niosomal form. There is prolonged release of drug from the plasma compartment with significantly lower peak levels; lower peak cardiac adriamycin concentrations with a shorter tissue half-life and decreased cardiac AUC and a greater degree of hepatic metabolism to inactive 7-deoxyaglycones. The tumour peak drug level and AUC was similar irrespective of the mode of administration of adriamycin. The growth delay (i.e. the time taken for the tumour volume to double) was significantly longer for adriamycin (15 days) and niosomal adriamycin (11 days) than for control (5.8 days). It is possible that the therapeutic ratio of adriamycin could be enhanced by administration in niosomal form. (Gregoriadis, 1976; Rahman et al., 1982) are examples. There is no doubt that in most cases the pharmacokinetics of the anticancer drug are altered, sometimes favourably, with a resultant decrement in toxicity. However, a number of problems remain to be overcome to provide a clinically useful carrier system, which include questions of (a) the specificity of the carrier for tumour cells in vivo, (b) the stability of the carrier complex in vivo, (c) the release of the active agent at the target site, (d) non-specific uptake of exogenous material by the reticuloendothelial systems (Poste, 1983) and (e) adverse immunological reactions to the exogenous carrier.A number of studies have demonstrated enhanced cytotoxicity of liposome-encapsulated drugs in vitro (Kimelberg & Mayhew, 1978). It has been proposed that this effect is mediated via increased cellular drug uptake by a fusional or endocytic process. However, there is controversy over the ability of liposomes to diffuse from the vascular compartment to the tumour interstitium or whether they would be phagocytosed by cells of the reticuloendothelial system. There is in vivo evidence, however, that administration of liposomes to tumour bearing rodents decreases adriamycin associated cardiac toxicity without loss of therapeutic effect (Forssen & Tokes, 1983;Olsen et al., 1982). A preliminary report of a phase I clinical study with liposome-associated adriamycin indicated that liposome administration is feasible and has potential advantages over free adriamycin with regard to some of its immediate toxic side effects (Gabizon et al., 1986 , 1985) and these preparations are used here. In this ...

show abstract

Section: Methodsmentioning

confidence: 99%

“…Preparation and c-haracterisation of niosomes Niosomes were prepared by the hand-shaking and etherinjection techniques which have been described previously (Baillie et al, 1985).…”

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer, spheroid and xenograft

Rogerson²,

Morrison³

et al. 1988

Br J Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Amongst various carriers utilized for target-oriented drug delivery, vesicular drug delivery systems in the form of liposome and niosomes have been most extensively investigated. Liposomal formulations have the limitation of poor stability and low drug entrapment efficiency while niosomes exhibit physical instability, aggregation, fusion, and leakage of entrapped drug, thus limiting the shelf-life of the dispersion [4,5]. Proniosomes [6] circumvent all the inherent drawbacks of niosomes and they offer a versatile vesicle delivery concept with the potential for targeted drug delivery.…”

Section: Introductionmentioning

confidence: 99%

Development and Targeting Efficiency of Irinotecan Engineered Proniosomes

Goudanavar¹,

Joshi²

2012

Trop. J. Pharm Res

View full text Add to dashboard Cite

“…Niosomes are vesicles of nonionic surfactant (for example, alkyl ester and alkyl ether) and cholesterol that act as a carrier for amphiphilic and lipophilic drugs [7,8,13,14]. Niosomes improve the therapeutic performance of encapsulated drug molecules by protecting the drug from harsh biological environments, resulting in their delayed clearance [15].…”

mentioning

confidence: 99%

Niosomes: a review of their structure, properties, methods of preparation, and medical applications

et al. 2017

View full text Add to dashboard Cite

Target-specific drug-delivery systems for the administration of pharmaceutical compounds enable the localization of drugs to diseased sites. Various types of drug-delivery systems utilize carriers, such as immunoglobulins, serum proteins, synthetic polymers, liposomes, and microspheres. The vesicular system of niosomes, with their bilayer structure assembled by nonionic surfactants, is able to enhance the bioavailability of a drug to a predetermined area for a period. The amphiphilic nature of niosomes promotes their efficiency in encapsulating lipophilic or hydrophilic drugs. Other additives, such as cholesterol, can be used to maintain the rigidity of the niosomes' structure. This narrative review describes fundamental aspects of niosomes, including their structural components, methods of preparation, limitations, and current applications to various diseases.

show abstract

The preparation and properties of niosomes—non-ionic surfactant vesicles

Cited by 376 publications

References 13 publications

Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer, spheroid and xenograft

Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer, spheroid and xenograft

Development and Targeting Efficiency of Irinotecan Engineered Proniosomes

Niosomes: a review of their structure, properties, methods of preparation, and medical applications

Contact Info

Product

Resources

About